COPD患者Treg/Th17免疫失衡及血清PCT水平与急性加重发作风险的关系

doi:10.3760/cma.j.issn.1007-1245.2024.22.023

摘要/Abstract

摘要：

目的　探讨慢性阻塞性肺疾病（COPD）患者调节性T细胞（Treg）/辅助性T细胞17（Th17）免疫失衡及血清降钙素原（PCT）水平与急性加重发作风险的关系。方法　回顾性分析2020年6月至2023年6月在西安医学院第二附属医院进行诊治的80例COPD患者临床资料，依据病情划分为COPD稳定期（SCOPD组，48例）和COPD急性加重期（AECOPD组，32例）。观察两组患者基础资料差异，采用多因素logistic回归分析AECOPD的危险因素，绘制受试者操作特征曲线（ROC）分析各项血清指标评估AECOPD的效能，采用Spearman相关性分析外周血Treg、Th17、Treg/Th17及PCT水平与AECOPD的关系。采用χ²检验、t检验。结果　AECOPD组中男20例，女12例，年龄（59.66±9.17）岁，病程（9.16±2.52）年；SCOPD组中男28例，女20例，年龄（60.13±9.05）岁，病程（8.98±2.14）年。AECOPD组Treg、Treg/Th17均低于SCOPD组［（2.52±0.48）%比（3.61±0.73）%、（0.54±0.16）比（1.10±0.33）］，差异均有统计学意义（t=7.435、8.913，均P<0.001）；AECOPD组Th17、PCT水平均高于SCOPD组［（4.64±0.95）%比（3.28±0.69）%、（1.33±0.46）µg/L比（0.75±0.32）µg/L］，差异均有统计学意义（t=7.417、6.656，均P<0.001）。经多因素logistic回归分析证实，Treg、Th17、Treg/Th17、PCT均是AECOPD的影响因素（均P<0.05）。ROC分析结果显示，外周血Treg、Th17、Treg/Th17及PCT水平均可用于AECOPD的评估，曲线下面积分别为0.895、0.910、0.932、0.803（均P<0.001）。相关性分析显示，外周血Treg、Treg/Th17均与AECOPD呈负相关，Th17、PCT水平均与AECOPD呈正相关（均P<0.05）。结论　Treg、Th17、Treg/Th17、PCT均是AECOPD的影响因素，且与AECOPD密切相关，可将以上指标作为评估AECOPD的标志物，为临床防治AECOPD提供参考。

关键词:

慢性阻塞性肺疾病, 调节性T细胞, 辅助性T细胞17, 免疫失衡, 降钙素原, 急性加重发作

Abstract:

Objective　To investigate the relationships between regulatory T cells (Treg) / helper T cell 17 (Th17) immune imbalance and serum procalcitonin (PCT) level and risk of acute exacerbation in patients with chronic obstructive pulmonary disease (COPD). Methods　The clinical data of 80 COPD patients diagnosed and treated in the Second Affiliated Hospital of Xi'an Medical University from June 2020 to June 2023 were analyzed retrospectively. According to their condition, they were divided into stable COPD patients (SCOPD group, 48 cases) and acute exacerbation of COPD patients (AECOPD group, 32 cases). The differences of basic data information between the two groups were observed. Multivariate logistic regression analysis was used to analyze the risk factors of AECOPD. The receiver operating characteristic curve (ROC) was drawn to analyze the efficacy of various serum indexes in evaluating AECOPD. Spearman correlation analysis was used to analyze the relationships between Treg, Th17, Treg/Th17, and PCT levels in the peripheral blood and AECOPD. χ² test and t test were used. Results　In the AECOPD group, there were 20 males and 12 females, aged (59.66±9.17) years, and the course of disease was (9.16±2.52) years. In the SCOPD group, there were 28 males and 20 females, aged (60.13±9.05) years, with a course of disease of (8.98±2.14) years. The levels of Treg and Treg/Th17 in the AECOPD group were lower than those in the SCOPD group [(2.52±0.48)% vs. (3.61±0.73)%, (0.54±0.16) vs. (1.10±0.33)], with statistically significant differences (t=7.435 and 8.913, both P<0.001). The levels of Th17 and PCT in the AECOPD group were higher than those in the SCOPD group [(4.64±0.95)% vs. (3.28±0.69)%, (1.33±0.46) μg/L vs. (0.75±0.32) μg/L], with statistically significant differences (t=7.417 and 6.656, both P<0.001). Multivariate logistic regression analysis confirmed that Treg, Th17, Treg/Th17, and PCT were the influencing factors of AECOPD (all P<0.05). ROC analysis showed that the levels of Treg, Th17, Treg/Th17, and PCT in the peripheral blood could be used to evaluate AECOPD, and the areas under the curves were 0.895, 0.910, 0.932, and 0.803, respectively (all P<0.001). Correlation analysis showed that peripheral blood Treg and Treg/Th17 were negatively correlated with AECOPD, and Th17 and PCT levels were positively correlated with AECOPD (all P<0.05). Conclusions　Treg, Th17, Treg/Th17, and PCT were all influencing factors of AECOPD and were closely related to AECOPD. These indicators could be used as markers to evaluate AECOPD and provide references for clinical prevention and treatment of AECOPD.

Key words:

Chronic obstructive pulmonary disease, Regulatory T cells, Helper T cell 17, Immune imbalance, Procalcitonin, Acute exacerbation

程旭东郭倩.

COPD患者Treg/Th17免疫失衡及血清PCT水平与急性加重发作风险的关系 [J]. 国际医药卫生导报, 2024, 30(22): 3807-3811.

Cheng Xudong, Guo Qian.

Relationships between Treg/Th17 immune imbalance and serum PCT level and risk of acute exacerbation in patients with COPD [J]. International Medicine and Health Guidance News, 2024, 30(22): 3807-3811.

参考文献

[1] 陈亚红. 2022年GOLD慢性阻塞性肺疾病诊断、治疗、管理及预防全球策略更新要点解读[J]. 中国全科医学,2022,25(11):1294-1304,1308. DOI:10.12114/j.issn.1007- 9572.2022.01.302.
[2] 成玮,李晓云,段佳熙,等. 慢性阻塞性肺疾病患者疼痛的研究进展[J]. 中国呼吸与危重监护杂志,2020,19(1):96-99. DOI:10.7507/1671-6205.201901051.
[3] van Eeden SF, Hogg JC. Immune-Modulation in chronic obstructive pulmonary disease: current concepts and future strategies[J]. Respiration, 2020, 99(7): 550-565. DOI: 10.1159/000502261.
[4] 陆燕芳,吴雅娟,郑江南,等. DCs、B10细胞和Th17/Treg失衡在慢性阻塞性肺疾病患者致病中的作用机制及其与肺功能的关联性[J]. 中国免疫学杂志,2023,39(12):2613-2618,2623. DOI:10.3969/j.issn.1000- 484X.2023.12.026.
[5] Li Z, Yuan X, Yu L, et al. Procalcitonin-guided antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease: an updated meta-analysis[J]. Medicine (Baltimore), 2019, 98(32): e16775. DOI: 10.1097/MD.0000000000016775.
[6] 刘韩韩,朱蕾. Th17/Treg在慢性阻塞性肺疾病中的研究进展[J]. 复旦学报(医学版),2023,50(1):147-153. DOI:10.3969/j.issn.1672-8467.2023.01.021.
[7] 张欣. 血液CC16、PCT、FKN水平与慢性阻塞性肺疾病患者衰弱的临床研究[J]. 河北医科大学学报,2023,44(9):1027-1031. DOI:10.3969/j.issn.1007-3205.2023.09.007.
[8] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志,2013,36(4):255-264. DOI:10.3760/cma.j.issn.1001- 0939.2013.04.007.
[9] Kim M, Doganay O, Hwang HJ, et al.Lobar ventilation in patients with COPD assessed with the full-scale airway network flow model and xenon-enhanced dual-energy CT[J]. Radiology,2021,299(2):201-209. DOI: 10.1148/radiol.2020202485.
[10] Hoult G, Gillespie D, Wilkinson TMA, et al. Biomarkers to guide the use of antibiotics for acute exacerbations of COPD (AECOPD): a systematic review and meta-analysis[J]. BMC Pulm Med, 2022, 22(1):194. DOI: 10.1186/s12890-022-01958-4.
[11] 刘彦,李虹伟,马清,等. 老年支气管扩张-慢性阻塞性肺疾病重叠综合征患者急性加重期的临床特点[J]. 临床和实验医学杂志,2017,16(16):1613-1616. DOI:10.3969/j.issn.1671-4695.2017.16.015.
[12] 孙印,何士杰,景卫革,等. 慢性阻塞性肺疾病免疫发病机制研究进展[J]. 医学综述,2019,25(13):2574-2578. DOI:10.3969/j.issn.1006-2084.2019.13.016.
[13] Zheng X, Zhang L, Chen J, et al. Dendritic cells and Th17/Treg ratio play critical roles in pathogenic process of chronic obstructive pulmonary disease[J]. Biomed Pharmacother, 2018, 108: 1141-1151. DOI: 10.1016/j.biopha.2018.09.113.
[14] Moraes L, Trias N, Brugnini A, et al. TH17/Treg imbalance and IL-17A increase after severe aneurysmal subarachnoid hemorrhage[J]. J Neuroimmunol, 2020, 346:577310. DOI: 10.1016/j.jneuroim.2020.577310.
[15] 刘兆阳. 外周血Th17/Treg失衡与老年稳定期COPD患者肺功能及急性加重的相关性[J]. 中国老年学杂志,2021,41(6):1199-1203. DOI:10.3969/j.issn.1005-9202.2021. 06.024.
[16] 张占强,吴春艳,方彬,等. Th17/Treg、IL-17在慢性阻塞性肺疾病患者中的表达及与肺功能的相关性[J]. 现代中西医结合杂志,2018,27(22):2419-2423,2494. DOI:10.3969/j.issn.1008-8849.2018.22.007.
[17] 黄林林,张楠. 老年COPD患者Treg/Th17免疫失衡与急性加重发作的关系及预测预后价值分析[J]. 中国急救复苏与灾害医学杂志,2023,18(1):94-97,105. DOI:10.3969/j.issn.1673-6966.2023.01.023.
[18] 潘彬,孙建,郑鹏城,等. 血清TK1、PCT、IL-6水平在AECOPD患者中的表达及其意义[J]. 标记免疫分析与临床,2020,27(7):1121-1124,1129. DOI:10.11748/bjmy.issn.1006-1703.2020.07.007.
[19] Zhang Q, Liu JX, Bai JS, et al. D-Dimer and procalcitonin improve the sensitivity of BAP-65 Score in predicting AECOPD patients admission to ICU[J]. Clin Lab, 2023,69(2):774-775. DOI: 10.7754/Clin.Lab.2022.220343.
[20] 李术环,徐慧莲,郝秋红. PCT、D-D、NLR、Cys-C与慢性阻塞性肺疾病急性加重期患者的相关性及对预后的预测价值[J]. 中华保健医学杂志,2023,25(4):426-428. DOI:103969/j.issn.1674-3245.2023.04.016.
[21] 谢小兵,高云,牛灵,等. 急性加重期和稳定期COPD患者血清CRP、IL-6、PCT及BNP水平变化[J]. 山东医药,2020,60(30):73-75. DOI:10.3969/j.issn.1002- 266X.2020.30.019.
[22] 赵丽.多索茶碱联合甲强龙治疗急性加重期COPD患者的疗效及对血清炎症因子水平的影响[J].哈尔滨医药,2023,43(2):5-7.DOI:10.3969/j.issn.1001-8131.2023.02.002.